search Created with Sketch.
search Created with Sketch.

Advertisement

Aesthetics Insider Mobile Logo
aethetics-insider Created with Sketch.

For the Duration: Dan Browne on Revance's Commitment to Innovation

April 6, 2018

Dan Browne, Steven Dayan, MD

With positive data now available from pivotal phase 3 SAKURA 1 and 2 trials, Revance is eyeing the potential opportunity to bring DaxibotulinumtoxinA for Injection (RT002) to market. Co-Founder, President & Chief Executive Officer Dan Browne talks to Steven Dayan, MD about the data, the pipeline, and the company's long-term focus.

Advertisement

In This Series

View More

Advertisement

Advertisement